查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1933355

全球輪狀病毒疫苗市場：市場規模、佔有率、成長率、產業分析、依類型、應用和地區劃分的考量、未來預測（2026-2034）

Rotavirus Vaccines Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 150 Pages | 商品交期: 請詢問到貨日

價格

輪狀病毒疫苗市場成長驅動因素

2025年全球輪狀病毒疫苗市場規模為52.2億美元，預計2026年將成長至55.7億美元，到2034年將達到128.6億美元，複合年增長率高達11.03%。北美地區在2025年佔市場主導地位，市佔率為8.53%。這得歸功於先進的醫療基礎設施、完善的疫苗接種計劃以及公眾對輪狀病毒感染的高度認知。輪狀病毒是一種高度傳染性的病毒，主要感染胃腸道，是嬰幼兒嚴重腹瀉和嘔吐的主要原因之一。 接種疫苗（通常作為常規免疫接種計劃的一部分口服）是最有效的預防措施。

市場動態

驅動因素：市場成長的主要驅動因素是各國免疫規劃的不斷擴大，特別是在東南亞、歐洲和北美地區。美國、德國和法國等國家已將輪狀病毒疫苗納入兒童常規免疫接種計畫。例如，印度國家免疫技術諮詢委員會 (NTAGI) 於 2019 年建議將輪狀病毒疫苗納入全民免疫規劃 (UIP)。此外，人們對輪狀病毒感染的認識不斷提高，以及聯合國兒童基金會 (UNICEF) 和全球疫苗免疫聯盟 (Gavi) 等國際組織的支持措施，也進一步推動了市場成長。

限制因素：供應鏈挑戰是市場擴張的障礙。輪狀病毒疫苗需要嚴格的冷鏈儲存和運輸，供應中斷可能促使暫時性短缺，並需要使用替代疫苗。 聯合國兒童基金會2024年報告稱，葛蘭素史克公司在2022年至2023年間的供應中斷迫使一些國家轉向替代產品，影響了疫苗的普及率。

機會：擴大疫苗接種覆蓋範圍帶來了成長機遇，尤其是在印度和中國等發展中國家。加強政府主導的措施以及將輪狀病毒疫苗納入國家免疫規劃，預計將推動疫苗接種覆蓋率和市場成長。 2024年，乍得在其擴大免疫規劃（EPI）下引入了輪狀病毒、瘧疾和肺炎球菌疾病疫苗，這反映了全球擴大疫苗接種覆蓋範圍的趨勢。

挑戰：疫苗安全問題，例如腸套疊（一種罕見的腸阻塞），可能會影響大眾認知並阻礙市場成長。根據美國疾病管制與預防中心2024年的數據，研究顯示接種疫苗後腸套疊的風險略有增加，凸顯了有效疫苗安全溝通的必要性。

市場趨勢

疫苗遞送方式的創新，例如可溶性貼片和新型注射配方，是一個顯著的趨勢。口服疫苗雖然方便，但由於酵素降解和首過效應，其生物利​​用度較低。 2025年，埃默里大學和美光生物醫學公司啟動了第一個輪狀病毒疫苗 "CC24" 的臨床試驗，該疫苗採用可溶性微陣列技術。這些進展凸顯了疫苗遞送方式正朝著更有效、更人性化的方向發展。

細分市場分析

依類型劃分：減毒活疫苗因其強效且持久的免疫反應而佔市場主導地位。 FDA核准的RotaTeq和RotaTeq疫苗是市場對減毒活疫苗依賴性的典型例證。 次單位疫苗，例如SK Chemicals的三價P2-VP8次單位疫苗，預計將推動未來的成長。

依產品劃分：RotaTeq佔市場佔有率領先地位，可預防五種輪狀病毒株，並已被納入國家免疫規劃，以降低住院率和死亡率。 ROTARIX憑藉其高效能性和在北美、歐洲和亞太等主要地區的核准，保持顯著的市場地位。

分銷管道：政府供應商佔主導地位，特別是透過像印度的全民免疫計劃（UIP）這樣的項目，該計劃確保免費獲得疫苗並擴大疫苗接種覆蓋範圍。 由於輪狀病毒病例和患者數量的增加，醫院和零售藥局也做出了顯著貢獻。

區域展望

北美：預計到2025年，市場規模將達到20.3億美元，到2026年將達到21.9億美元。這一增長得益於先進的醫療基礎設施、高疫苗接種率和研發能力。

歐洲：自2006年Rotarix和RotaTeq獲批上市以來，歐洲市場已佔顯著的市場佔有率，降低了因輪狀病毒性腸胃炎促使的住院率（每年7.5萬至15萬例）。

亞太地區：該地區正經歷最快的成長，這主要得益於龐大的兒童人口、政府主導的舉措以及公眾意識的提高。在東南亞，輪狀病毒感染佔兒童腹瀉病例的40.8%。

拉丁美洲、中東和非洲：政府主導的措施以及全球疫苗免疫聯盟（Gavi）和聯合國兒童基金會等組織的支持，正透過低成本疫苗幫助提高疫苗覆蓋率，從而實現穩步增長。

目錄

第一章：引言

第二章：摘要整理

第三章：市場動態

  • 市場驅動因素
  • 市場限制因素
  • 市場機遇
  • 市場趨勢

第四章：關鍵考慮因素

  • 輪狀病毒感染發生率/盛行率（2025 年）
  • 主要公司新產品發布
  • 主要公司產品線分析
  • 輪狀病毒疫苗接種建議/指南
  • 輪狀病毒疫苗接種計畫概述
  • 輪狀病毒疫苗技術進展
  • 主要產業趨勢：併購、業務合作等

第五章 全球輪狀病毒疫苗市場分析：洞察與預測（2021-2034）

  • 市場分析、洞察與預測：依類型劃分
    • 減毒活疫苗
    • 其他
  • 市場分析、洞察與預測：依產品劃分
    • Rotarix
    • RotaTeq
    • Rotasil
    • Rotovac
    • 其他
  • 市場分析、洞察與預測：依通路劃分
    • 醫院和零售藥局
    • 政府供應商
    • 其他
  • 市場分析、洞察與預測：依地區劃分
    • 北美美洲
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲

第六章 北美輪狀病毒疫苗市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 美國
    • 加拿大

第七章 歐洲輪狀病毒疫苗市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 英國
    • 德國
    • 法國
    • 西班牙
    • 義大利
    • 斯堪的納維亞半島
    • 歐洲其他地區

第八章 亞太地區輪狀病毒疫苗市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 日本
    • 中國
    • 印度
    • 澳大利亞
    • 東南亞
    • 亞太其他地區

第九章：拉丁美洲輪狀病毒疫苗市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 巴西
    • 墨西哥
    • 拉丁美洲其他地區

第十章：中東與非洲輪狀病毒疫苗市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 海灣合作委員會（GCC）國家/地區
    • 南非
    • 中東和非洲其他地區

第十一章 競爭分析

  • 全球市佔率分析（2025 年）
  • 公司簡介
    • GSK plc
    • Merck &Co. Inc.
    • Serum Institute of India Pvt. Ltd.
    • Sanofi
    • Bharat Biotech
    • SINOVAC
Product Code: FBI113730

Growth Factors of rotavirus vaccines Market

The global rotavirus vaccines market was valued at USD 5.22 billion in 2025 and is projected to grow to USD 5.57 billion in 2026, reaching USD 12.86 billion by 2034, exhibiting a strong CAGR of 11.03%. North America dominated the market in 2025, with a market share of 8.53%, driven by advanced healthcare infrastructure, robust vaccination programs, and strong public awareness about rotavirus infections. Rotavirus, a highly contagious virus affecting the gastrointestinal tract, is a leading cause of severe diarrhea and vomiting in infants. Vaccination, usually administered orally as part of routine immunization schedules, is the most effective preventive measure.

Market Dynamics

Drivers: A major factor driving market growth is the increasing adoption of national immunization programs, particularly in Southeast Asia, Europe, and North America. Countries like the U.S., Germany, and France have integrated rotavirus vaccines into routine childhood immunizations. For instance, in India, the National Technical Advisory Group on Immunization (NTAGI) recommended including the rotavirus vaccine in the Universal Immunization Programme (UIP) in 2019. Additionally, rising awareness of rotavirus infections and supportive initiatives by international organizations, such as UNICEF and Gavi, are further bolstering market growth.

Restraints: Supply chain challenges pose a constraint on market expansion. Rotavirus vaccines require strict cold-chain storage and transport, and disruptions can lead to temporary shortages or the use of alternative vaccines. UNICEF reported in 2024 that several countries had to switch to alternative products due to supply disruptions from GSK in 2022-2023, which impacted adoption rates.

Opportunities: Expanding vaccination coverage offers growth opportunities, particularly in developing countries such as India and China. Increased government initiatives and inclusion of rotavirus vaccines in national immunization schedules are expected to raise vaccine uptake and market growth. In 2024, Chad introduced vaccines for rotavirus, malaria, and pneumococcal infections under the Expanded Programme on Immunization, reflecting a global trend toward broader preventive coverage.

Challenges: Vaccine safety concerns, such as intussusception (a rare bowel obstruction), may influence public perception and hinder market growth. According to CDC data in 2024, studies indicate a slight increase in intussusception risk post-vaccination, emphasizing the need for effective communication on vaccine safety.

Market Trends

Innovation in vaccine delivery, such as dissolvable patches and novel parenteral formulations, is a prominent trend. Oral vaccines, while convenient, have low bioavailability due to enzymatic degradation and first-pass metabolism. In 2025, Emory University and Micron Biomedical initiated the first clinical trial of CC24, a rotavirus vaccine delivered via dissolvable microarray technology. Such developments highlight the ongoing shift toward more effective and patient-friendly vaccine delivery methods.

Segmentation Analysis

By Type: The live attenuated vaccine segment dominates due to strong, long-lasting immune responses. FDA-approved vaccines like ROTARIX and RotaTeq exemplify the market's reliance on live attenuated formulations. Subunit vaccines, such as the trivalent P2-VP8 candidate by SK Chemicals, are under development and expected to drive future growth.

By Product: RotaTeq holds the leading share, protecting against five rotavirus strains and included in national immunization programs, reducing hospitalization and mortality. ROTARIX remains significant due to its high potency and approval across major regions, including North America, Europe, and Asia Pacific.

By Distribution Channel: Government suppliers dominate, particularly through programs like India's UIP, ensuring free vaccine access and expanding coverage. Hospitals and retail pharmacies contribute significantly due to increasing rotavirus cases and high patient flow.

Regional Outlook

North America: Market valued at USD 2.03 billion in 2025, projected to reach USD 2.19 billion in 2026, led by advanced healthcare infrastructure, high vaccination rates, and R&D capabilities.

Europe: Holds a substantial share, supported by ROTARIX and RotaTeq approvals since 2006, reducing hospitalization rates from rotavirus gastroenteritis (75,000-150,000 annually).

Asia Pacific: Fastest-growing region due to large pediatric populations, government initiatives, and rising awareness. Rotavirus accounts for 40.8% of diarrheal diseases in Southeast Asian children.

Latin America & Middle East & Africa: Expected to grow steadily due to government initiatives and support from organizations like Gavi and UNICEF, which provide vaccines at low cost to improve coverage.

Competitive Landscape

The market is concentrated, with key players including GSK plc., Merck & Co., Inc., Serum Institute of India Pvt. Ltd., Sanofi, Bharat Biotech, and SINOVAC. Companies focus on product innovation, distribution partnerships, and R&D investments. For example, GSK received FDA approval in 2022 for a new liquid ROTARIX vaccine, and Merck expanded RotaTeq supply to China in 2018, demonstrating strategic market positioning.

Conclusion

The global rotavirus vaccines market is poised for significant growth, from USD 5.22 billion in 2025 to USD 5.57 billion in 2026, and reaching USD 12.86 billion by 2034 at a CAGR of 11.03%. Growth is driven by national immunization programs, increasing pediatric populations, innovative vaccine formulations, and government initiatives supporting equitable vaccine access. North America remains a dominant region, while Asia Pacific emerges as the fastest-growing market. Despite challenges like supply chain disruptions and safety concerns, robust R&D and expansion of vaccination coverage are expected to sustain market momentum over the forecast period.

Segmentation By Type

  • Live Attenuated
  • Others

By Product

  • ROTARIX
  • RotaTeq
  • ROTASIIL
  • ROTOVAC
  • Others

By Distribution Channel

  • Hospital & Retail Pharmacies
  • Government Suppliers
  • Others

By Geography

  • North America (By Type, Product, Distribution Channel, and Country/Sub-region)
    • U.S.
    • Canada
  • Europe (By Type, Product, Distribution Channel, and Country/Sub-region)
    • Germany
    • U.K.
    • France
    • Spain
    • Italy
    • Scandinavia
    • Rest of Europe
  • Asia Pacific (By Type, Product, Distribution Channel, and Country/Sub-region)
    • China
    • Japan
    • India
    • Australia
    • Southeast Asia
    • South Korea
    • Rest of Asia Pacific
  • Latin America (By Type, Product, Distribution Channel, and Country/Sub-region)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa (By Type, Product, Distribution Channel, and Country/Sub-region)
    • GCC
    • South Africa
    • Rest of the Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Incidence/Prevalence of Rotavirus Infection, 2025
  • 4.2. New Product Launches, By Key Players
  • 4.3. Pipeline Analysis, By Key Players
  • 4.4. Recommendations/Guidelines for Rotavirus Vaccines
  • 4.5. Overview: Vaccination Schedule for Rotavirus
  • 4.6. Technological Advancements in the Rotavirus Vaccines
  • 4.7. Key Industry Developments Such as Mergers, Acquisitions, and Partnerships

5. Global Rotavirus Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Type
    • 5.1.1. Live Attenuated
    • 5.1.2. Others
  • 5.2. Market Analysis, Insights and Forecast - By Product
    • 5.2.1. ROTARIX
    • 5.2.2. RotaTeq
    • 5.2.3. ROTASIIL
    • 5.2.4. ROTOVAC
    • 5.2.5. Others
  • 5.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.3.1. Hospital & Retail Pharmacies
    • 5.3.2. Government Suppliers
    • 5.3.3. Others
  • 5.4. Market Analysis, Insights and Forecast - By Region
    • 5.4.1. North America
    • 5.4.2. Europe
    • 5.4.3. Asia Pacific
    • 5.4.4. Latin America
    • 5.4.5. Middle East & Africa

6. North America Rotavirus Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Type
    • 6.1.1. Live Attenuated
    • 6.1.2. Others
  • 6.2. Market Analysis, Insights and Forecast - By Product
    • 6.2.1. ROTARIX
    • 6.2.2. RotaTeq
    • 6.2.3. ROTASIIL
    • 6.2.4. ROTOVAC
    • 6.2.5. Others
  • 6.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 6.3.1. Hospital & Retail Pharmacies
    • 6.3.2. Government Suppliers
    • 6.3.3. Others
  • 6.4. Market Analysis, Insights and Forecast - By Country
    • 6.4.1. U.S.
    • 6.4.2. Canada

7. Europe Rotavirus Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Type
    • 7.1.1. Live Attenuated
    • 7.1.2. Others
  • 7.2. Market Analysis, Insights and Forecast - By Product
    • 7.2.1. ROTARIX
    • 7.2.2. RotaTeq
    • 7.2.3. ROTASIIL
    • 7.2.4. ROTOVAC
    • 7.2.5. Others
  • 7.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 7.3.1. Hospital & Retail Pharmacies
    • 7.3.2. Government Suppliers
    • 7.3.3. Others
  • 7.4. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 7.4.1. U.K.
    • 7.4.2. Germany
    • 7.4.3. France
    • 7.4.4. Spain
    • 7.4.5. Italy
    • 7.4.6. Scandinavia
    • 7.4.7. Rest of Europe

8. Asia Pacific Rotavirus Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Type
    • 8.1.1. Live Attenuated
    • 8.1.2. Others
  • 8.2. Market Analysis, Insights and Forecast - By Product
    • 8.2.1. ROTARIX
    • 8.2.2. RotaTeq
    • 8.2.3. ROTASIIL
    • 8.2.4. ROTOVAC
    • 8.2.5. Others
  • 8.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 8.3.1. Hospital & Retail Pharmacies
    • 8.3.2. Government Suppliers
    • 8.3.3. Others
  • 8.4. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 8.4.1. Japan
    • 8.4.2. China
    • 8.4.3. India
    • 8.4.4. Australia
    • 8.4.5. Southeast Asia
    • 8.4.6. Rest of Asia Pacific

9. Latin America Rotavirus Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Type
    • 9.1.1. Live Attenuated
    • 9.1.2. Others
  • 9.2. Market Analysis, Insights and Forecast - By Product
    • 9.2.1. ROTARIX
    • 9.2.2. RotaTeq
    • 9.2.3. ROTASIIL
    • 9.2.4. ROTOVAC
    • 9.2.5. Others
  • 9.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 9.3.1. Hospital & Retail Pharmacies
    • 9.3.2. Government Suppliers
    • 9.3.3. Others
  • 9.4. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 9.4.1. Brazil
    • 9.4.2. Mexico
    • 9.4.3. Rest of Latin America

10. Middle East & Africa Rotavirus Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 10.1. Market Analysis, Insights and Forecast - By Type
    • 10.1.1. Live Attenuated
    • 10.1.2. Others
  • 10.2. Market Analysis, Insights and Forecast - By Product
    • 10.2.1. ROTARIX
    • 10.2.2. RotaTeq
    • 10.2.3. ROTASIIL
    • 10.2.4. ROTOVAC
    • 10.2.5. Others
  • 10.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 10.3.1. Hospital & Retail Pharmacies
    • 10.3.2. Government Suppliers
    • 10.3.3. Others
  • 10.4. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 10.4.1. GCC
    • 10.4.2. South Africa
    • 10.4.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2025)
  • 11.2. Company Profiles
    • 11.2.1. GSK plc
      • 11.2.1.1. Overview
      • 11.2.1.2. Services
      • 11.2.1.3. SWOT Analysis
      • 11.2.1.4. Recent Developments
      • 11.2.1.5. Strategies
      • 11.2.1.6. Financials (Based on Availability)
    • 11.2.2. Merck & Co. Inc.
      • 11.2.2.1. Overview
      • 11.2.2.2. Services
      • 11.2.2.3. SWOT Analysis
      • 11.2.2.4. Recent Developments
      • 11.2.2.5. Strategies
      • 11.2.2.6. Financials (Based on Availability)
    • 11.2.3. Serum Institute of India Pvt. Ltd.
      • 11.2.3.1. Overview
      • 11.2.3.2. Services
      • 11.2.3.3. SWOT Analysis
      • 11.2.3.4. Recent Developments
      • 11.2.3.5. Strategies
      • 11.2.3.6. Financials (Based on Availability)
    • 11.2.4. Sanofi
      • 11.2.4.1. Overview
      • 11.2.4.2. Services
      • 11.2.4.3. SWOT Analysis
      • 11.2.4.4. Recent Developments
      • 11.2.4.5. Strategies
      • 11.2.4.6. Financials (Based on Availability)
    • 11.2.5. Bharat Biotech
      • 11.2.5.1. Overview
      • 11.2.5.2. Services
      • 11.2.5.3. SWOT Analysis
      • 11.2.5.4. Recent Developments
      • 11.2.5.5. Strategies
      • 11.2.5.6. Financials (Based on Availability)
    • 11.2.6. SINOVAC
      • 11.2.6.1. Overview
      • 11.2.6.2. Services
      • 11.2.6.3. SWOT Analysis
      • 11.2.6.4. Recent Developments
      • 11.2.6.5. Strategies
      • 11.2.6.6. Financials (Based on Availability)

List of Tables

  • Table 1: Global Rotavirus Vaccines Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 2: Global Rotavirus Vaccines Market Revenue (USD billion) Forecast, by Product, 2021-2034
  • Table 3: Global Rotavirus Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 4: Global Rotavirus Vaccines Market Revenue (USD billion) Forecast, by Region, 2021-2034
  • Table 5: North America Rotavirus Vaccines Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 6: North America Rotavirus Vaccines Market Revenue (USD billion) Forecast, by Product, 2021-2034
  • Table 7: North America Rotavirus Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 8: North America Rotavirus Vaccines Market Revenue (USD billion) Forecast, By Country, 2021-2034
  • Table 9: Europe Rotavirus Vaccines Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 10: Europe Rotavirus Vaccines Market Revenue (USD billion) Forecast, by Product, 2021-2034
  • Table 11: Europe Rotavirus Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 12: Europe Rotavirus Vaccines Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 13: Asia Pacific Rotavirus Vaccines Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 14: Asia Pacific Rotavirus Vaccines Market Revenue (USD billion) Forecast, by Product, 2021-2034
  • Table 15: Asia Pacific Rotavirus Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 16: Asia Pacific Rotavirus Vaccines Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 17: Latin America Rotavirus Vaccines Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 18: Latin America Rotavirus Vaccines Market Revenue (USD billion) Forecast, by Product, 2021-2034
  • Table 19: Latin America Rotavirus Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 20: Latin America Rotavirus Vaccines Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 21: Middle East & Africa Rotavirus Vaccines Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 22: Middle East & Africa Rotavirus Vaccines Market Revenue (USD billion) Forecast, by Product, 2021-2034
  • Table 23: Middle East & Africa Rotavirus Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 24: Middle East & Africa Rotavirus Vaccines Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034

List of Figures

  • Figure 1: Global Rotavirus Vaccines Market Revenue Breakdown (USD billion, %) by Region, 2025 & 2034
  • Figure 2: Global Rotavirus Vaccines Market Value Share (%), by Type, 2025 & 2034
  • Figure 3: Global Rotavirus Vaccines Market Value Share (%), by Product, 2025 & 2034
  • Figure 4: Global Rotavirus Vaccines Market Value Share (%), by Distribution Channel, 2025 & 2034
  • Figure 5: Global Rotavirus Vaccines Market Value Share (%), by Region, 2025 & 2034
  • Figure 6: North America Rotavirus Vaccines Market Value (USD billion), by Type, 2025 & 2034
  • Figure 7: North America Rotavirus Vaccines Market Value Share (%), by Type, 2025
  • Figure 8: North America Rotavirus Vaccines Market Value (USD billion), by Product, 2025 & 2034
  • Figure 9: North America Rotavirus Vaccines Market Value Share (%), by Product, 2025
  • Figure 10: North America Rotavirus Vaccines Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 11: North America Rotavirus Vaccines Market Value Share (%), by Distribution Channel, 2025
  • Figure 12: North America Rotavirus Vaccines Market Value (USD billion), By Country, 2025 & 2034
  • Figure 13: North America Rotavirus Vaccines Market Value Share (%), By Country, 2025
  • Figure 14: Europe Rotavirus Vaccines Market Value (USD billion), by Type, 2025 & 2034
  • Figure 15: Europe Rotavirus Vaccines Market Value Share (%), by Type, 2025
  • Figure 16: Europe Rotavirus Vaccines Market Value (USD billion), by Product, 2025 & 2034
  • Figure 17: Europe Rotavirus Vaccines Market Value Share (%), by Product, 2025
  • Figure 18: Europe Rotavirus Vaccines Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 19: Europe Rotavirus Vaccines Market Value Share (%), by Distribution Channel, 2025
  • Figure 20: Europe Rotavirus Vaccines Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 21: Europe Rotavirus Vaccines Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 22: Asia Pacific Rotavirus Vaccines Market Value (USD billion), by Type, 2025 & 2034
  • Figure 23: Asia Pacific Rotavirus Vaccines Market Value Share (%), by Type, 2025
  • Figure 24: Asia Pacific Rotavirus Vaccines Market Value (USD billion), by Product, 2025 & 2034
  • Figure 25: Asia Pacific Rotavirus Vaccines Market Value Share (%), by Product, 2025
  • Figure 26: Asia Pacific Rotavirus Vaccines Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 27: Asia Pacific Rotavirus Vaccines Market Value Share (%), by Distribution Channel, 2025
  • Figure 28: Asia Pacific Rotavirus Vaccines Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 29: Asia Pacific Rotavirus Vaccines Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 30: Latin America Rotavirus Vaccines Market Value (USD billion), by Type, 2025 & 2034
  • Figure 31: Latin America Rotavirus Vaccines Market Value Share (%), by Type, 2025
  • Figure 32: Latin America Rotavirus Vaccines Market Value (USD billion), by Product, 2025 & 2034
  • Figure 33: Latin America Rotavirus Vaccines Market Value Share (%), by Product, 2025
  • Figure 34: Latin America Rotavirus Vaccines Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 35: Latin America Rotavirus Vaccines Market Value Share (%), by Distribution Channel, 2025
  • Figure 36: Latin America Rotavirus Vaccines Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 37: Latin America Rotavirus Vaccines Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 38: Middle East & Africa Rotavirus Vaccines Market Value (USD billion), by Type, 2025 & 2034
  • Figure 39: Middle East & Africa Rotavirus Vaccines Market Value Share (%), by Type, 2025
  • Figure 40: Middle East & Africa Rotavirus Vaccines Market Value (USD billion), by Product, 2025 & 2034
  • Figure 41: Middle East & Africa Rotavirus Vaccines Market Value Share (%), by Product, 2025
  • Figure 42: Middle East & Africa Rotavirus Vaccines Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 43: Middle East & Africa Rotavirus Vaccines Market Value Share (%), by Distribution Channel, 2025
  • Figure 44: Middle East & Africa Rotavirus Vaccines Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 45: Middle East & Africa Rotavirus Vaccines Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 46: Global Rotavirus Vaccines Market Share (%), By Company, 2025